欧美成人动漫日韩国庆_亚洲天堂自拍偷拍_人妻少妇边接电话边娇喘_新婚少妇交换杨雨婷_高清不卡一区二区在线观看_亚洲国产中文另类久久久精品网站_十八禁裸体自慰免费观看_日本亚洲中文有码_日本人zzzwww色视频直播_国产福利姬在线观看

Ribo obtained an implied license for clinical trials of its new drug for treatment of metastatic prostate cancer

Suzhou Ribo Life Science Co., Ltd. has recently obtained an implied license for clinical trials of its innovative ASO drug ISIS 560131, which had been introduced and developed by Ribo, following review by the Center for Drug Evaluation under the National Medical Products Administration.

Ribo raised 470 million yuan in its Series C2 financing

Suzhou Ribo Life Science Co., Ltd. announced today that 470 million yuan was raised during its Series C2 financing. In this round of financing, the lead investors included China Venture Capital Fund Corporation Ltd., CICC Qide Fund, and GL Ventures, and the co-investors included renowned investment institutes such as Hengxu Capital, Everest VC, Sinopharm-CICC Capital, Shenzhen Co-way Capital Services Co., Ltd., Shanghai Free Trade Zone Equity Fund Management Co., Ltd., and Hongtao Capital

Ribo raised 200 million yuan in its Series C1 financing

On December 5, 2019, Suzhou Ribo Life Science Co. Ltd., announced the successful completion of Series C1 financing worth RMB 203 million.

Ribo completed the enrollment of the first patient into the Chinese phase II clinical trial on ASOISIS449884 Injection

Suzhou Ribo Life Science Co., Ltd. today announced that its phase II clinical trial of ISIS449884 Injection, an ASO for the treatment of type 2 diabetes, had completed the enrollment of the first patient and the subject was successfully administered the first dose of study drug.

Ribo was selected as one of 2019 "Most Innovative Pharmaceutical Companies in Asia" by Clarivate Analytics